Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve Submission of Prior ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has called a board meeting on 14 August 2025 with a packed agenda. Key items include approval of Q1 FY26 (quarter ended 30 June 2025) standalone financial results along with the auditor's limited review report. The board will also finalise the notice and logistics for the 31st Annual General Meeting and approve the Board Report for FY25. Two new directors are proposed: Ms. Mayuri Baidya as an Additional Non-Executive Independent Director and Gattu Gnana Prakash as an Additional Non-Executive Non-Independent Director. Additionally, the company plans to allot equity shares on conversion of warrants from a prior preferential issue. The company is also seeking shareholder approval to raise its borrowing limits under Section 180(1)(c), enable creation of charges on its assets under Section 180(1)(a), increase investment and loan limits under Section 186, and approve transactions under Section 185 of the Companies Act. The trading window for insiders is closed from 1 July 2025 until 48 hours after the board meeting concludes.
The agenda signals potential capital raising (warrant conversion, higher borrowing limits, asset pledging) which could dilute existing shareholders or increase debt burden. Shareholders should watch the Q1 FY26 results closely and review the AGM notice for details on the proposed borrowings, related-party transactions, and new director appointments.